Radstone Capital Group

Radstone Capital Group
Institutional Platform Across Private Credit and Healthcare Innovation
Radstone Capital Group is a private family held Australian-Malaysian investment holding group with strategic partnerships globally. The Group operates through a cohesive portfolio of specialist entities, each focused on high-conviction investment themes within private credit, medical technology, and healthcare services. The Group is structured to deliver disciplined deployment of capital, institutional governance, and long-term value creation across all its verticals.
RAB Capital Sdn Bhd serves as the Group's principal investing entity for deploying capital into the invoice factoring segment—a private credit strategy that provides liquidity to creditworthy businesses against trade receivables. RAB Capital manages end-to-end deployment through to execution and servicing of trade finance transactions with specialist factoring partners. With a proven track record in managing complex receivables portfolios, RAB Capital plays a central role in the Group's operations, ensuring disciplined risk management and transaction-level visibility.
Medicare Capital Group is the Group's healthcare-focused brand. Via Radstone Lifesciences (Australia), It holds equity in Opum Technologies, a U.S.-based medical technology firm specializing in AI-driven orthotic solutions that support post-operative recovery and musculoskeletal rehabilitation. In Malaysia, Medicare Capital is a key strategic partner to an Australian medical tourism platform, focused on high-quality, cross-border dental care and expanding into broader medical verticals.
Together, these entities reflect Radstone's integrated platform approach—where investment expertise, operational capability, and regulated structuring converge to deliver value across sectors and geographies. The Group maintains a clear focus on governance, scalability, and alignment of interests with its partners and counterparties.
Private Credit – High-Yield, Asset-Backed Financing through Invoice Factoring
Creating Sustainable Value Through Short-Term Receivables Financing
Asset Class
Investment Structure
Risk Management
Liquidity
High-quality receivables from vendors supplying to creditworthy obligors—public listed companies, GLCs, and multinationals. Robust returns with lower risk profiles than traditional unsecured lending.
Capital deployed through structured factoring arrangements where invoices are purchased at a discount and collected at full value upon maturity. This provides the group with legal title to the underlying assets and contractual rights against obligors, creating multiple security layers.
All transactions undergo rigorous vendor and obligor due diligence with legal assignment, corporate guarantees, and controlled accounts. Our risk framework evaluates multiple risk factors, emphasizing obligor payment history and vendor performance. 
With 30-90 day transaction cycles, this strategy enables frequent capital recycling and minimal market correlation. Unlike traditional private equity with 3-5 year lockups, our factoring strategy offers quarterly liquidity windows with short notice periods.
Radstone Capital Group operates within Malaysia’s growing invoice factoring market, often utilising dedicated Special Purpose Vehicles where appropriate to structure transactions and facilitate counterpart relationships. In an environment where traditional bank financing remains constrained by bureaucracy and risk aversion, Radstone provides direct liquidity to businesses—anchored by disciplined underwriting and real-economy exposure.
Factoring remains an underappreciated segment of private credit, particularly in emerging markets. With a proprietary pipeline of high-quality invoices, established compliance frameworks, and strong origination capabilities, Radstone is strategically positioned for scalable and sustainable growth. The Group’s long-standing relationships with leading corporates in Malaysia and across Southeast Asia provide privileged access to premium transaction flow and recurring deal opportunities.
Medical Technology – Investing in Data-Driven Healthcare Transformation
Wearable Diagnostics
Opum's platform integrates advanced sensor technology with real-time patient data to enable accurate monitoring of joint and muscle function—crucial for post-surgery recovery, physiotherapy, and orthopedic assessments.
AI-Driven Treatment Insights
Proprietary machine learning algorithms help clinicians personalise treatment pathways based on objective data, improving outcomes and reducing recovery timelines.
Clinical Utility
The system is already deployed across leading clinics and hospitals, including orthopaedic and rehabilitation centres, with strong adoption by surgeons and therapists seeking evidence-based care models.
Scalable Commercial Model
Cloud-based software-as-a-service (SaaS) offering, enabling scalable deployment across geographies and care settings.
Medicare Capital Group leads the Group's innovation-led healthcare platform, focusing on transformative medical technologies that combine clinical efficacy with commercial scalability. Our core investment is in Opum Technologies, a US based healthtech firm redefining musculoskeletal care through intelligent diagnostics.
By investing in Opum, Medicare Capital Group is championing a new paradigm in healthcare—where data meets design, and patient outcomes drive value creation. We believe the future of medicine is precision-led, non-invasive, and digitally delivered—and Radstone is proud to play a leading role in shaping that future.
Radstone is also a partner with an Australian healthcare provider to drive patients under a unique medical tourism proposition to Malaysia from Australia.
Strong Leadership Team: A Wealth of Expertise
Radstone Capital Group's leadership team brings decades of experience in finance, commerce and trade, ensuring the company's growth and success in the competitive factoring market.
Ramesh Kana
Group Chief Executive Officer & Director - RAB Capital Sdn Bhd
Ramesh Kana brings over three decades of global CEO and CFO experience across investment management, private credit, and industrial corporates. As Group CEO of Radstone Capital Group, he leads a platform focused on structured, high-yield investments in trade receivables, healthcare, and sustainability-driven assets across Malaysia, Australia, and the U.S. His prior leadership roles include Group CEO of Emery Oleochemicals—then a top-three global oleochemicals firm—and senior executive positions globally at Royal Dutch Shell and Lynas Corporation. Ramesh is widely recognised for his ability to build disciplined, scalable investment platforms with strong governance and risk oversight. He was an early mover in Malaysia's invoice factoring space, enabling institutional deployment into a real-economy asset class with robust collateral structures. His governance credentials include three terms as Chair of the UN Global Compact (Malaysia & Brunei). With a deep understanding of regulatory frameworks, investor alignment, and cross-border execution, Ramesh anchors Radstone's credibility and appeal to institutional capital providers.
Ian G Palmer
Director - RAB Capital Sdn Bhd
Ian G. Palmer is a Director of RAB Capital Sdn Bhd with four decades of regional and multinational experience in finance, capital markets and supply-chain commerce. He began his career at Arthur Andersen in Singapore covering regional clients. He subsequently joined Citibank Singapore as Vice President, Financial Control, overseeing Asia Pacific consumer banking and reporting directly to New York headquarters. He left Citibank to take on a new challenge - joining US based ARCO Chemicals as General Manager, Special Projects, building Asia Pacific infrastructure databases to support petrochemical supply. Ian later went back in to the financial services sector, joining GK Goh, a well established Singapore based securities firm. He became Company Secretary and Senior Vice President, International Operations, with responsibilities across the Philippines, Hong Kong and Indonesia. In 2004, Ian founded and continues to lead AAKK Pte Ltd, a Singapore-based regional commodities trading firm serving the Asia Pacific region. He brings deep expertise in cross-border supply-chain financing, risk governance, regulatory compliance and financial control, underpinned by hands-on operating experience across industries and jurisdictions. He advises boards strategically.
Norliza Rayyan
Chief Business Development Officer
Norliza Rayyan brings over 35 years of leadership experience in retail and Islamic banking, wealth management, and investor relations. She is currently Chief Business Development Officer within the Radstone Capital Group, where she plays a pivotal role in engaging high-net-worth investors for structured private credit offerings. Her foundational expertise was built over three decades at HSBC Bank Malaysia, where she held senior roles across retail banking, regulatory compliance, personal banking, and Islamic financial services. She is recognised for her ability to lead high-performing teams, restructure underperforming business units, and integrate technology to drive profitability. Norliza also provides advisory input on Shariah-compliant product design and governance, reinforcing Radstone's alignment with ethical and faith-based investment mandates. A graduate of the Women in Leadership program by TalentCorp and ICAEW, she holds an MBA (with Merit) from Anglia Ruskin University (UK). She is also a Certified Financial Planner (CFP).
Contact Us
B1011. Block B. Phileo Damansara 2. Jalan Damansara. Petaling Jaya. 46350. Selangor. Malaysia
Tel. +603 7499 5911